2025-04-04T13:17:26-05:00 2024-06-30 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2023-07-01 231907729 BREAKTHROUGH T1D BREA 8005332873 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 MAGGIE MORRIS CHIEF FINANCIAL OFFICER 2124797550 2025-04-04 1 0 EVAN W SEEKAMP P01907071 2127589700 2025-04-02 2023 2025-03-06 01:10:19Z MAGGIE MORRIS 200 VESEY STREET NEW YORK NY 10281 507831471 0 X WWW.BREAKTHROUGHT1D.ORG X 1970 PA IMPROVING LIVES BY ACCELERATING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D. SEE SCHEDULE O. 15 14 632 235000 52045 30420 190086200 211575057 19620834 21841702 9232479 23163370 4858572 1535328 223798085 258115457 101810267 97664746 0 0 70340964 78986288 2370683 1254831 41127862 41238028 54224289 215759942 232130154 8038143 25985303 446188087 488117647 139007857 157047946 307180230 331069701 X IN JUNE 2024, JDRF INTERNATIONAL INTRODUCED A NEW BRAND AND UNDERWENT A LEGAL NAME CHANGE TO BREAKTHROUGH T1D. BREAKTHROUGH T1D IS THE LEADING GLOBAL T1D ORGANIZATION WORKING TO ACCELERATE LIFE-CHANGING BREAKTHROUGHS TO CURE, PREVENT, AND TREAT T1D AND ITS COMPLICATIONS. 0 0 97664746 97664746 21841702 RESEARCH FUNDING - FOR THE YEAR ENDED JUNE 30, 2024, BREAKTHROUGH T1D (FORMERLY JDRF) DIRECTLY FUNDED RESEARCH GRANTS AND INDUSTRY AGREEMENTS FOR WHICH $103.5 MILLION IN RESEARCH GRANT EXPENSE, NET WAS RECOGNIZED ACCORDING TO GAAP IN ADDITION TO $18 MILLION OF PROGRAMMATIC RESEARCH INVESTMENTS THAT ARE RECORDED ON BREAKTHROUGH T1D'S BALANCE SHEET. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO DIRECT RESEARCH FUNDING, SEE SCHEDULE O. 50773834 RESEARCH SUPPORT - BREAKTHROUGH T1D (FORMERLY JDRF) MAINTAINS AN IN-HOUSE TEAM OF SKILLED SCIENTIFIC, MEDICAL, POLICY, AND GOVERNMENT RELATIONS PROFESSIONALS WHO PLAY A CRITICAL ROLE IN LEADING AND SUPPORTING THE EVALUATION OF RESEARCH FUNDING OPPORTUNITIES BY BREAKTHROUGH T1D AND INFLUENCING RESEARCH DIRECTION AND THE DISBURSEMENT OF RESEARCH FUNDS FROM OTHERS. THESE PROFESSIONALS ALSO WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE THAT RESEARCH CAN PROCEED WITHOUT DELAY AND RESULTS ARE UNDERSTOOD BY HEALTHCARE DECISION MAKERS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO RESEARCH SUPPORT, SEE SCHEDULE O. 24270340 PUBLIC EDUCATION AND OUTREACH - BREAKTHROUGH T1D (FORMERLY JDRF) EDUCATES THE COMMUNITY ABOUT TYPE 1 DIABETES (T1D) AND ITS COMPLICATIONS AND PROVIDES SUPPORT SERVICES AND RESOURCES TO NEWLY DIAGNOSED CHILDREN AND ADULTS, THEIR FAMILIES, AND OTHERS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO PUBLIC EDUCATION AND OUTREACH, SEE SCHEDULE O. 172708920 1 1 0 1 0 0 0 0 0 1 1 0 1 0 1 1 0 1 0 1 1 1 0 1 1 1 0 1 0 1 0 0 0 0 0 0 1 0 1 0 0 0 1 0 0 0 0 1 541 2 1 632 1 1 1 0 0 0 0 1 1 0 0 0 1 0 0 0 X 15 14 0 0 1 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC TN TX UT VT VA WA WV WI WY X X MAGGIE MORRIS 8005332873 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 DRAYTON VIRKLER BOARD MEMBER 3.00 0.00 X 0 0 0 MATT VAREY CHAIR, AUDIT & RISK COMMITTEE 5.00 0.00 X 0 0 0 CHRISTOPHER TURNER BOARD MEMBER 3.00 0.00 X 0 0 0 JENNIFER SCHNEIDER MD CHAIR, NOMINATING & GOV COMMITTEE 5.00 0.00 X 0 0 0 JEFF PLUMER BOARD MEMBER 3.00 0.00 X 0 0 0 CARLTON MCMILLAN DIRECTOR 3.00 0.00 X 0 0 0 JOE LACHER JR BOARD MEMBER 3.00 0.00 X 0 0 0 KAREN JORDAN CHAIR, FUNDING COMMITTEE 5.00 0.00 X 0 0 0 CLAUDIA GRAHAM PHD CHAIR, ADVOCACY & IMPACT COMMITTEE 5.00 0.00 X 0 0 0 ELIZABETH CASWELL CHAIR, RESEARCH COMMITTEE 5.00 0.00 X 0 0 0 MICHAEL ALTER BOARD MEMBER 3.00 0.00 X 0 0 0 MICHELLE GRIFFIN VICE CHAIR OF THE BOARD 5.00 0.00 X X 0 0 0 GRANT BEARD CHAIR OF THE BOARD 5.00 0.00 X X 0 0 0 LISA WALLACK CHAIR, TALENT & COMPENSATION COMMITTEE 5.00 0.00 X 0 0 0 KAREY L WITTY CHAIR, FINANCE & INVESTMENT COMMITTEE 5.00 0.00 X 0 0 0 AARON KOWALSKI CHIEF EXECUTIVE OFFICER 50.00 0.00 X 861917 0 68678 SYDNEY YOVIC CHF. STR OFC/CHF OF STAFF (END 6/24) 50.00 0.00 X 318243 0 63480 ROBERT KING CFAO/TREASURER 50.00 0.00 X 520154 0 24840 JESSE RABEN CHIEF LEGAL & RISK OFC, SECRETARY 50.00 0.00 X 165639 0 37916 STEVEN ST PETER MANAGING DIRECTOR, T1D FUND 50.00 0.00 X 767591 0 56106 SANJOY DUTTA PHD CHIEF SCIENTIFIC OFFICER 50.00 0.00 X 416535 0 10556 HELEN ELLIAS MANAGING DIR. T1D FUND (END 6/24) 50.00 0.00 X 569145 0 45397 KATHLEEN SEITZ CHIEF GLOBAL DEVELOPMENT OFFICER 50.00 0.00 X 446673 0 27076 TRACY MIDO CHIEF HUMAN RESOURCES OFFICER 50.00 0.00 X 360389 0 12895 PAMELA MORRISROE CHIEF MARKETING OFFICER 50.00 0.00 X 445368 0 46392 ESTHER LATRES VICE PRESIDENT, RESEARCH 50.00 0.00 X 276278 0 11627 BALA BALASUBRAMANIAN CHIEF INFORMATION OFFICER 50.00 0.00 X 341819 0 58929 AMY MONTALTO VICE PRESIDENT, VOLUNTEER ENGAGEMENT 50.00 0.00 X 274950 0 61078 TIMOTHY DOYLE FORMER OFFICER 0.00 0.00 X 268477 0 0 JAMES MCDONALD BOARD LIAISON 50.00 0.00 X 135629 0 8586 6168807 0 533556 245 1 1 0 BEYOND TECHNOLOGIES LLC 201 N ILLINOIS ST 16TH FLOOR INDIANAPOLIS IN 46204 IT CONSULTING 929186 CENTRIC CONSULTING LLC PO BOX 75581 CLEVELAND OH 44104 IT CONSULTING 899181 INNOVATION CLOUD LLC 356 OSWEGO CT WEST NEW YORK NY 07093 IT CONSULTING 701261 COMMUNITY COUNSELING SERVICE CO LLC 527 MADISON AVE 5TH FL NEW YORK NY 10022 FUNDRAISING CONSULTING 700000 STEPHANIE A RELKIN LLC 96 CARLYLE PLACE ROSLYN HEIGHTS NY 11577 MARKETING CONSULTING 408750 41 2929176 100183747 108462134 12307878 211575057 PROGRAM RELATED INVEST 541714 21841702 21841702 21841702 12063436 52045 12011391 1246568 1246568 50669 0 50669 50669 50669 235984101 224884167 11099934 11099934 11099934 30303747 100183747 24806997 5496750 5496750 496510 24850 471660 471660 MISC REVENUE 900099 126833 126833 GRANT REFUNDS & ADJUST 813212 -5857152 -5857152 -5730319 258115457 0 52045 46488355 67075228 67075228 30589518 30589518 4633518 2928025 1328076 377417 78605 46762 8859 22984 59491370 33524088 7704804 18262478 1912019 1063934 249528 598557 8378336 4520292 1204127 2653917 4492440 2525500 624443 1342497 812250 221520 499430 91300 330475 330475 930654 930654 1254831 1254831 637893 637893 12001512 6796020 1708892 3496600 6762112 4610446 457440 1694226 2700588 1580556 340696 779336 5013776 2827528 799925 1386323 5145973 2963058 670603 1512312 3971926 2576025 286044 1109857 2712406 1015626 274314 1422466 13918 10740 884 2294 6778283 3896545 938878 1942860 668465 322229 169625 176611 OUTREACH EXPENSES 2455465 1899376 119284 436805 FUNDR. POSTAGE & PRINT 2162785 2162785 DUES, FEES, & SUB 1139773 665758 176260 297755 -13965 119492 -237108 103651 232130154 172708920 18293372 41127862 X 5618584 1286360 0 4332224 588029 2761954 12512865 11061849 50188103 59146772 2859833 4222183 6689096 5456587 10110542 11341060 35298921 27638673 10078950 7660248 270968509 308741402 393344 363245 63438834 60188873 18359982 17173474 446188087 488117647 13191296 17099900 96425875 113596253 6416162 4696215 22974524 21655578 139007857 157047946 X 247180317 262669904 59999913 68399797 307180230 331069701 446188087 488117647 25985303 -2095832 0 X 0 1 X 1 0 X 194074339 190647071 203302047 189472784 211575057 989071298 194074339 190647071 203302047 189472784 211575057 989071298 989071298 2918738 2297884 2679458 8011697 13307590 29215367 29579 58494 72762 23845 30420 215100 1671720 3345522 22507054 23469681 16111383 67105360 1085607125 0.91110 0.93240 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: PROGRAM RELATED INVESTMENT INCOME OTHER EXCLUDED INCOME - 2019 AMOUNT: $ 1,671,720. 2020 AMOUNT: $ 3,345,522. 2021 AMOUNT: $ 22,507,054. 2022 AMOUNT: $ 23,469,681. 2023 AMOUNT: $ 16,111,383. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 0 1 37250 1 10500 0 1 568782 0 1 519624 1136156 0 PART II-B, LINE 1: GENERAL STATEMENT OF ACTIVITIES BREAKTHROUGH T1D IS THE LEADING GLOBAL ORGANIZATION FUNDING TYPE 1 DIABETES (T1D) RESEARCH, FOCUSED ON CURING T1D AND IMPROVING LIVES. BREAKTHROUGH T1D'S ADVOCACY INCLUDES NON-PARTISAN LOBBYING ACTIVITY TO ENSURE CONGRESS CONTINUES TO INVEST IN CRITICALLY IMPORTANT MEDICAL RESEARCH AND PUTS IN PLACE POLICIES TO ADVANCE DEVELOPMENT AND ACCESS TO THERAPIES TO CURE T1D AND HELP PEOPLE STAY AS HEALTHY AS POSSIBLE UNTIL THAT DAY. BREAKTHROUGH T1D HAS BEEN INSTRUMENTAL IN SECURING THE RENEWAL OF THE SPECIAL DIABETES PROGRAM, WHICH PROVIDES $150M ANNUALLY FOR T1D RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH. BREAKTHROUGH T1D STAFF AND VOLUNTEERS COMMUNICATE WITH GOVERNMENT OFFICIALS THROUGH EMAIL, PHONE CALLS, AND MEETINGS, TO EDUCATE THEM ON ISSUES AND ENCOURAGE THE ADVANCEMENT OF LEGISLATION. FY24 LOBBYING ACTIVITIES DO NOT REPRESENT A SUBSTANTIAL PART OF THE ORGANIZATION'S OVERALL ACTIVITIES. 7872557 790019 303284 8359292 7584083 503698 215224 7872557 8911983 25000 -1144983 207917 7584083 7709169 2111094 908280 8911983 7887833 -140727 33086 71023 7709169 0.00000 1.00000 0.00000 0 0 2684066 783191 1900875 32614855 26855482 5759373 7660248 T1D FUND PROGRAM RELATED INVESTMENTS 60188873 F 60188873 LIABILITIES RELATED TO SPLIT-INTEREST AGREEMENTS 2430093 OPERATING & FINANCE LEASE LIABILITY 19225485 21655578 X 261861756 -2095832 622872 -1472960 263334716 637893 -5857152 -5219259 258115457 237972285 622872 5857152 6480024 231492261 637893 637893 232130154 PART V, LINE 4: ORGANIZATION'S ENDOWMENT FUNDS THE ORGANIZATION UTILIZES EARNINGS ON ENDOWMENT FUNDS IN THE MANNER SPECIFIED BY THE DONOR AND/OR FOR SUPPORTING THE ORGANIZATION'S GENERAL EXEMPT PURPOSE. PART X, LINE 2: UNCERTAIN TAX POSITIONS BREAKTHROUGH T1D IS A NOT-FOR-PROFIT ORGANIZATION EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (IRC) AND IS ORGANIZED UNDER THE LAWS OF THE COMMONWEALTH OF PENNSYLVANIA. THE EFFECT OF INCOME TAX POSITIONS IS RECOGNIZED ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO BREAKTHROUGH T1D'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER IRC SECTION 511. BREAKTHROUGH T1D'S UNRELATED BUSINESS INCOME TAX LIABILITY WAS INSIGNIFICANT FOR THE YEARS ENDED JUNE 30, 2024 AND 2023. PART XI, LINE 4B - OTHER ADJUSTMENTS: GRANT REFUNDS & ADJUSTMENTS -5,857,152. 1 EAST ASIA AND THE PACIFIC 1 GRANTMAKING RESEARCH GRANTS 4161358 NORTH AMERICA GRANTMAKING RESEARCH GRANTS 3919694 EUROPE 3 GRANTMAKING RESEARCH GRANTS 19937111 MIDDLE EAST AND NORTH AFRICA GRANTMAKING RESEARCH GRANTS 2553322 SOUTH ASIA GRANTMAKING RESEARCH GRANTS 318033 EUROPE PROGRAM SERVICES RESEARCH SUPPORT 204507 NORTH AMERICA INVESTMENTS INVESTMENTS 3000000 EUROPE INVESTMENTS INVESTMENTS 11692132 EAST ASIA AND THE PACIFIC INVESTMENTS INVESTMENTS 1473196 EUROPE FUNDRAISING ACTIVITIES FUNDRAISING ACTIVITIES 333345 0 4 0 0 0 4 45786157 1806541 47592698 EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 1594887 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 98397 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 290000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 144100 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA T1D RESEARCH 399973 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 66500 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 255000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 479959 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 507132 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 646294 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA T1D RESEARCH 500000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 880244 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 249664 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 533327 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 199896 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 170000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 100000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 891788 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 184223 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 1127242 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA T1D RESEARCH 156936 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA T1D RESEARCH 946412 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA T1D RESEARCH 300000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 374732 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 749870 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 581926 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 300000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 514830 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 774226 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 200000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 249342 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 449427 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 164500 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 948222 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 599261 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 249779 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 200000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 750000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 66383 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 175000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 415269 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 350379 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 200000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 421904 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 198972 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 45879 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 668744 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 637197 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 320000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 145638 CHECK/WIRE TRANSFER 0 N/A N/A SOUTH ASIA T1D RESEARCH 318033 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 210250 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 325709 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 200856 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 502870 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 2500000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 733160 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA T1D RESEARCH 250000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 759036 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 240221 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 447030 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 300000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 559316 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 1171031 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 138553 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 400000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 200000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 160000 CHECK/WIRE TRANSFER 0 N/A N/A 0 68 1 0 1 0 0 1 PART I, LINE 2: GRANT MONITORING PROCEDURES RESEARCH GRANTS ARE AWARDED BY BREAKTHROUGH T1D WITH THE SUPPORT OF BREAKTHROUGH T1D'S RESEARCH COMMITTEE COMPRISED OF BREAKTHROUGH T1D BOARD MEMBERS AND OTHER VOLUNTEERS FOLLOWING THE RECOMMENDATIONS OF AN IN-HOUSE TEAM OF PROFESSIONAL SCIENTIFIC STAFF AND WITH INPUT FROM EXTERNAL SCIENTIFIC REVIEWERS. THE REVIEW PROCESS INCLUDES THE FOLLOWING CRITERIA: (1) THE SCIENTIFIC MERIT OF THE PROPOSED RESEARCH OUTLINED IN A GRANT APPLICATION AND (2) THE RELATIONSHIP OF THE PROPOSED RESEARCH TO BREAKTHROUGH T1D'S GOAL TO IMPROVE LIVES TODAY AND TOMORROW BY ACCELERATING LIFE-CHANGING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D AND ITS COMPLICATIONS. THE SCIENTIFIC RESEARCH TEAM AND GRANT ADMINISTRATION STAFF MAINTAIN CLOSE CONTACT WITH GRANTEES, PROVIDING ADVICE AND EVALUATION, REVIEWING PROGRESS REPORTS, REVIEWING RESEARCH EXPENDITURES VERSUS AGREED BUDGETS, AND HELPING DISSEMINATE RESEARCH RESULTS. PART I, LINE 3, COLUMN (F): AMOUNTS IN COLUMN F ARE REPORTED ON AN ACCRUAL BASIS IN LINE WITH THE ORGANIZATION'S AUDITED FINANCIAL STATEMENTS. PART II, LINES 2 AND 3 WHILE MANY FOREIGN GRANTEES MAY BE RECOGNIZED AS CHARITIES IN THEIR RESPECTIVE COUNTRY OR AS 501(C)(3) ORGANIZATIONS BY THE IRS, BREAKTHROUGH T1D DOES NOT HAVE A FEASIBLE WAY TO VALIDATE FOREIGN TAX EXEMPTION AND CONSERVATIVELY CLASSIFIES ALL FOREIGN GRANTEES AS OTHER. X X X X X X 1 BLUE STATE DIGITAL 41 FLATBUSH AVENUE 8TH FL BROOKLYN NY 11217 DIRECT APPEAL FUNDRAISING SERVICES 0 3791639 596411 3195228 THE PURSUANT GROUP 15660 NORTH DALLAS PARKWAY SUITE 1 DALLAS TX 75248 DIRECT APPEAL FUNDRAISING SERVICES 0 2529049 417564 2111486 CASWELL ZACHRY GRIZZARD 6301 GASTON AVENUE SUITE 715 DALLAS TX 75214 PLANNED GIVING MARKETING 0 0 121745 -121745 COMMUNITY COUNSELING SERVICE CO LLC 527 MADISON AVE 5TH FLOOR NEW YORK NY 10022 COMPREHENSIVE CAMPAIGN ADVISORY SERVICES 0 0 92500 -92500 SYNERGY DIRECT MARKETING SOLUTIONS LLC 480 WEST TUSCARAWAS AVE SUITE 307 BARBERTON OH 44203 TEXT MESSAGING CAMPAIGN 0 0 26611 -26611 6320688 1254831 5065858 AL AK AZ AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI ILLINOIS GALA 18170983 16658068 1512915 154293 376489 418691 128148 HOUSTON PROMISE BALL 2852400 1937580 914820 5579 39824 303631 208556 111914 304 109464111 81588099 27876012 12421 806735 5045872 3582312 6544503 7068029 130487494 100183747 30303747 12421 812314 5239989 4262432 7171750 7308091 24806997 5496750 496510 10000 14850 0 496510 10000 14850 24850 471660 AL AK AZ CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI 1 0 0 0 1.00000 KIMBERLY ZINGALEMANAGERFINANCIAL REPORTING AND COMPLIANCE-BREAKTHROUGH T1 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 0 ROBERT KING CFO - BREAKTHROUGH T1D FILING GAMING APPLICATIONS AND REPORTS. NO PORTION OF COMPENSATION IS SPECIFICALLY ALLOCABLE TO GAMING MANAGEMENT. X 0 PART I, LINE 2: SEPARATE FROM PROFESSIONAL FUNDRAISING SERVICES REPORTED ON SCHEDULE G, PART I, BREAKTHROUGH T1D PAID FUNDRAISING EXPENSES OF $470,229 FOR POSTAGE AND $1,671,486 FOR PRINTING TO THE PURSUANT GROUP. THE INVOICES PROVIDE AN ITEMIZED LIST OF SERVICES AND EXPENSES. PART I, LINE 2: SEPARATE FROM PROFESSIONAL FUNDRAISING SERVICES REPORTED ON SCHEDULE G, PART I, BREAKTHROUGH T1D PAID FUNDRAISING EXPENSES OF $28,472 FOR POSTAGE TO CASWELL. THE INVOICES PROVIDE AN ITEMIZED LIST OF SERVICES AND EXPENSES. 1 ADVANCED REGENERATIVE MANUFACTURING INSTITUTE (ARMI) 400 COMMERCIAL STREET MANCHESTER NH 03101 813327581 501(C)(6) 418000 0 N/A N/A T1D RESEARCH ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 830621846 501(C)(3) 660056 0 N/A N/A T1D RESEARCH ANN & ROBERT H LURIE CHILDREN'S HOSPITAL OF CHICAGO 225 EAST CHICAGO AVE PO BOX 10 CHICAGO IL 60611 362170833 501(C)(3) 679850 0 N/A N/A T1D RESEARCH ARIZONA BOARD OF REGENTS UNIVERSITY OF ARIZONA PO BOX 3520 TUCSON AZ 857223520 742652689 501(C)(3) 995758 0 N/A N/A T1D RESEARCH BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON TX 77030 741613878 501(C)(3) 321293 0 N/A N/A T1D RESEARCH BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 E DUARTE ROAD DUARTE CA 91010 953432210 501(C)(3) 1500000 0 N/A N/A T1D RESEARCH BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE - NA SEATTLE CA 981012795 910653422 501(C)(3) 640325 0 N/A N/A T1D RESEARCH BOSTON CHILDREN'S HOSPITAL PO BOX 414413 BOSTON MA 022414413 042774441 501(C)(3) 800000 0 N/A N/A T1D RESEARCH BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS ST BOSTON MA 02115 042312909 501(C)(3) 813378 0 N/A N/A T1D RESEARCH BROWN UNIVERSITY 164 ANGELL ST PO BOX 1929 PROVIDENCE RI 02912 050258809 501(C)(3) 158283 0 N/A N/A T1D RESEARCH CALIFORNIA INSTITUTE OF TECHNOLOGY 1200 E CALIFORNIA BLVD MAIL CODE 234-6 PASADENA CA 91125 951643307 501(C)(3) 250000 0 N/A N/A T1D RESEARCH CARNEGIE MELLON UNIVERSITY 5000 FORBES AVENUE PITTSBURGH PA 15213 250969449 501(C)(3) 928460 0 N/A N/A T1D RESEARCH CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVE STE 357 CLEVELAND OH 441063052 341018992 501(C)(3) 400000 0 N/A N/A T1D RESEARCH CHILDREN'S HOSPITAL OF PHILADELPHIA 3501 CIVIC CENTER BLVD CTRB RM 5100 PHILADELPHIA PA 19104 231352166 501(C)(3) 149999 0 N/A N/A T1D RESEARCH CHILDREN'S MERCY HOSPITAL 2401 GILLHAM ROAD KANSAS CITY MO 64108 440605373 501(C)(3) 236811 0 N/A N/A T1D RESEARCH COLORADO SCHOOL OF MINES 1500 ILLINOIS ST GOLDEN CO 80401 846000551 501(C)(3) 300000 0 N/A N/A T1D RESEARCH CRITICAL PATH INSTITUTE (C-PATH) 1730 EAST RIVER ROAD 200 TUCSON AZ 85718 201999134 501(C)(3) 644330 0 N/A N/A T1D RESEARCH DIATECH DIABETES INC 88 UNION AVE MEMPHIS TN 38103 841890342 N/A 210000 0 N/A N/A T1D RESEARCH DUKE UNIVERSITY 4010 ADOLFO ROAD SUITE A CAMARILLO CA 93012 560532129 501(C)(3) 625659 0 N/A N/A T1D RESEARCH EVOQ THERAPEUTICS INC 1600 HURON PARKWAY BLG 520 2ND FL ANN ARBOR MI 48109 813291966 N/A 150000 0 N/A N/A T1D RESEARCH GEISINGER CLINIC 100 N ACADEMY AVE DANVILLE PA 178223057 236291113 501(C)(3) 325604 0 N/A N/A T1D RESEARCH GEORGIA TECH RESEARCH CORPORATION PO BOX 100117 ATLANTA GA 30384 580603146 501(C)(3) 202165 0 N/A N/A T1D RESEARCH GINER INC 89 RUMFORD AVE NEWTON MA 02466 821416958 N/A 154650 0 N/A N/A T1D RESEARCH HUMACYTE 2525 E NC HWY 54 STE 104 DURHAM NC 27713 841661297 N/A 240000 0 N/A N/A T1D RESEARCH ILLINOIS INSTITUTE OF TECHNOLOGY 3424 S STATE STSTE TC-4TH FL RM 4C8-2 CHICAGO IL 606163717 362170136 501(C)(3) 94788 0 N/A N/A T1D RESEARCH INDIANA BIOSCIENCES RESEARCH INSTITUTE 1345 W 16TH ST STE 300 INDIANAPOLIS IN 46202 462882271 501(C)(3) 544898 0 N/A N/A T1D RESEARCH INDIANA UNIVERSITY OFFICE OF RESEARCH ADMIN DEPT PO BOX 66057 INDIANAPOLIS IN 462666057 356001673 501(C)(3) 1589054 0 N/A N/A T1D RESEARCH INTEGRATED MEDICAL SENSORS INC 30 HUGHES SUITE 200 IRVINE CA 92618 474751319 N/A 130000 0 N/A N/A T1D RESEARCH IQVIA INC 100 IMS DRIVE PARSIPPANY NJ 07054 271341991 N/A 583769 0 N/A N/A T1D RESEARCH ITOLERANCE INC 1951 NW 7TH AVE STE 300 MIAMI FL 33136 853086959 N/A 250000 0 N/A N/A T1D RESEARCH JAEB CENTER FOR HEALTH RESEARCH 15310 AMBERLY DRIVE STE 350 TAMPA FL 33647 593187624 501(C)(3) 150000 0 N/A N/A T1D RESEARCH JOHNS HOPKINS UNIVERSITY 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 520595110 501(C)(3) 819247 0 N/A N/A T1D RESEARCH JOSLIN DIABETES CENTER INC ONE JOSLIN PLACE BOSTON MA 022155306 042203836 501(C)(3) 2499700 0 N/A N/A T1D RESEARCH MASSACHUSETTS GENERAL HOSPITAL 101 HUNTINGTON AVE 3RD FLOOR BOSTON MA 02199 042697983 501(C)(3) 449213 0 N/A N/A T1D RESEARCH MEMORIAL SLOAN-KETTERING CANCER CENTER 1275 YORK AVENUE BOX 701 NEW YORK NY 10065 131924236 501(C)(3) 250000 0 N/A N/A T1D RESEARCH MICHIGAN STATE UNIVERSITY 426 AUDITORIUM RD RM 2 EAST LANSING MI 488242613 386005984 501(C)(3) 250000 0 N/A N/A T1D RESEARCH MINUTIA 535 BELLEVUE AVE UNIT 8 OAKLAND CA 94610 851020286 N/A 236450 0 N/A N/A T1D RESEARCH NEMOURS CHILDREN'S CLINIC 10140 CENTURION PARKWAY NORTH JACKSONVILLE FL 32256 590634433 501(C)(3) 215780 0 N/A N/A T1D RESEARCH NEURODON LLC 9800 CONNECTICUT DRIVE CROWN POINT IN 46307 465375254 N/A 156400 0 N/A N/A T1D RESEARCH NEW YORK MEDICAL COLLEGE 40 SUNSHINE COTTAGE RD ADMIN BLDG VALHALLA NY 10595 131099420 501(C)(3) 250000 0 N/A N/A T1D RESEARCH NORTHWESTERN UNIVERSITY 633 CLARK ST ROOM G-547 CROWN EVANSTON IL 60208 362167817 501(C)(3) 840492 0 N/A N/A T1D RESEARCH RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA PO BOX 400195 OFFICE OF SPONSORED PROGRAMS CHARLOTTESVILLE VA 229044195 546001796 501(C)(3) 1257109 0 N/A N/A T1D RESEARCH REGENTS OF THE UNIVERSITY OF COLORADO 1800 GRANT STREET 8TH FLOOR DENVER CO 80203 846000555 501(C)(3) 4736958 0 N/A N/A T1D RESEARCH REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE ST RM 1054 ANN ARBOR MI 48109 386006309 501(C)(3) 1755465 0 N/A N/A T1D RESEARCH REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 PO BOX 1450 MINNEAPOLIS MN 554855957 416007513 501(C)(3) 1142291 0 N/A N/A T1D RESEARCH REMD BIOTHERAPEUTICS 4010 ADOLFO ROAD STE A CAMARILLO CA 93012 454614986 N/A 155000 0 N/A N/A T1D RESEARCH RTI INTERNATIONAL PO BOX 14668 RESEARCH TRIANGLE PARK NC 27709 560686338 501(C)(3) 1406247 0 N/A N/A T1D RESEARCH RUTGERS BIOMEDICAL AND HEALTH SCIENCES 65 DAVIDSON ROAD STE 306 PISCATAWAY NJ 088545602 462354111 501(C)(3) 450762 0 N/A N/A T1D RESEARCH RUTGERS THE STATE UNIVERSITY OF NEW JERSEY 33 KNIGHTSBRIDGE ROAD 2ND FL EAST WING PISCATAWAY NJ 088543925 226001086 501(C)(3) 125729 0 N/A N/A T1D RESEARCH SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 6400 SANGER ROAD ORLANDO FL 328277400 510197108 501(C)(3) 330000 0 N/A N/A T1D RESEARCH STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 441444253 941156365 501(C)(3) 1007571 0 N/A N/A T1D RESEARCH T1D EXCHANGE INC 11 AVENUE DE LAFAYETTE 5TH FL BOSTON MA 02111 451623549 501(C)(3) 1379034 0 N/A N/A T1D RESEARCH THE LUNDQUIST INSTITUTE 1124 WEST CARSON ST TORRANCE CA 90502 952138184 501(C)(3) 149999 0 N/A N/A T1D RESEARCH THE MEDICAL COLLEGE OF WISCONSIN INC 8701 WATERTOWN PLANK ROAD MILWAUKEE WI 53226 390806261 501(C)(3) 317695 0 N/A N/A T1D RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES 11000 KINROSS AVE 211PO BOX 951406 LOS ANGELES CA 900951406 956006143 501(C)(3) 534899 0 N/A N/A T1D RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM ST STE 425 BOX 0897 SAN FRANCISCO CA 94143 946036493 501(C)(3) 3852335 0 N/A N/A T1D RESEARCH THE UNIVERSITY OF CHICAGO 1427 EAST 60TH STREET STE 120 CHICAGO IL 60637 362177139 501(C)(3) 487652 0 N/A N/A T1D RESEARCH TIDEPOOL 555 BRYANT ST 429 PALO ALTO CA 94301 462302287 501(C)(3) 1500000 0 N/A N/A T1D RESEARCH TORRAMICS INC 440 N BARRANCA AVE 2897 COVINA CA 91723 872652308 N/A 350000 0 N/A N/A T1D RESEARCH TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA P-221 FRANKLIN BLG 3451 WALNUT STREET PHILADELPHIA PA 191785541 231352685 501(C)(3) 640683 0 N/A N/A T1D RESEARCH UNIVERSITY OF ALABAMA AT BIRMINGHAM 701 SOUTH 20TH ST AB 990 BIRMINGHAM AL 352940109 636005396 501(C)(3) 249881 0 N/A N/A T1D RESEARCH UNIVERSITY OF CALIFORNIA SAN DIEGO UCSD CASHIERS OFFICE-9500 GILMAN DRIVE DEPT 0009 LA JOLLA CA 920930009 956006144 501(C)(3) 735846 0 N/A N/A T1D RESEARCH UNIVERSITY OF CALIFORNIA SANTA BARBARA 1212 SAASB SANTA BARBARA CA 93106 956006145 501(C)(3) 537638 0 N/A N/A T1D RESEARCH UNIVERSITY OF CINCINNATI PO BOX 932641 CLEVELAND OH 441930014 316000989 501(C)(3) 511821 0 N/A N/A T1D RESEARCH UNIVERSITY OF FLORIDA 123 GRINTER HALL PO BOX 113001 GAINESVILLE FL 326113001 596002052 501(C)(3) 3660683 0 N/A N/A T1D RESEARCH UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC 3901 RAINBOW BLVD MSN 1039 KANSAS CITY KS 661032937 481108830 501(C)(3) 549999 0 N/A N/A T1D RESEARCH UNIVERSITY OF MARYLAND 4101 CHESAPEAKE BLG 4300 TERRAPIN TRAIL COLLEGE PARK MD 207423141 526002033 501(C)(3) 329999 0 N/A N/A T1D RESEARCH UNIVERSITY OF MIAMI 1400 NW 10TH AVENUE 10TH FLOOR- MIAMI FL 33136 590624458 501(C)(3) 2321216 0 N/A N/A T1D RESEARCH UNIVERSITY OF NOTRE DAME 836A GRACE HALL NOTRE DAME IN 46556 350868188 501(C)(3) 150000 0 N/A N/A T1D RESEARCH UNIVERSITY OF PITTSBURGH PO BOX 371220 PITTSBURGH PA 152517220 250965591 501(C)(3) 300000 0 N/A N/A T1D RESEARCH UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE ROOM 406 SALT LAKE CITY UT 84112 876000525 501(C)(3) 601339 0 N/A N/A T1D RESEARCH UNIVERSITY OF WASHINGTON 3917 UNIVERSITY WAY NE SEATTLE WA 98195 916001537 501(C)(3) 1009467 0 N/A N/A T1D RESEARCH UNIVERSITY OF WISCONSIN-MADISON UW-MADISON GAR ACCOUNT OFFICE DRAWER538 MILWAUKEE WI 532780538 396006492 501(C)(3) 703559 0 N/A N/A T1D RESEARCH UT SOUTHWESTERN PO BOX 841753 DALLAS TX 752841753 752556007 501(C)(3) 915644 0 N/A N/A T1D RESEARCH VANDERBILT UNIVERSITY MEDICAL CENTER (VUMC) DOF DEPT AT 40303 ATLANTA GA 31192 352528741 501(C)(3) 1064609 0 N/A N/A T1D RESEARCH WASHINGTON UNIVERSITY CAMPUS BOX 1034-700 ROSEDALE AVE ST LOUIS MO 631121408 430653611 501(C)(3) 675000 0 N/A N/A T1D RESEARCH WAYNE STATE UNIVERSITY 5057 WOODWARD AVE 13TH FL DETROIT MI 482024050 386028429 501(C)(3) 274499 0 N/A N/A T1D RESEARCH WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1 RUE MICHEL-SERVET NEW YORK NY 10065 131623978 501(C)(3) 325000 0 N/A N/A T1D RESEARCH WILLIAM MARSH RICE UNIVERSITY 6100 MAIN STREET - MS 16 HOUSTON TX 770051892 741109620 501(C)(3) 200000 0 N/A N/A T1D RESEARCH YALE UNIVERSITY PO BOX 209010 - 10 AMISTAD ST NEW HAVEN CT 065209010 060646973 501(C)(3) 502819 0 N/A N/A T1D RESEARCH BETH ISRAEL DEACONESS MEDICAL CENTER IN 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 699999 0 N/A N/A T1D RESEARCH COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK PO BOX 29789-GENERAL POST OFFICE NEW YORK NY 100879789 135598093 501(C)(3) 488704 0 N/A N/A T1D RESEARCH HARVARD COLLEGE PO BOX 415649 BOSTON MA 022415649 042103580 501(C)(3) 4095000 0 N/A N/A T1D RESEARCH X-THERMA INC 2600 HILLTOP DR RICHMON CA 948061971 472474292 N/A 80250 0 N/A N/A T1D RESEARCH VANDERBILT UNIVERSITY PMB 407749 - 2301 VANDERBILT PLACE NASHVILLE TN 372407749 620476822 501(C)(3) 274970 0 N/A N/A T1D RESEARCH HUGO W MOSER RESEARCH INSTITUTE AT KENNEDY KRIEGER 707 N BROADWAY BALTIMORE MD 21205 521524967 501(C)(3) 65000 0 N/A N/A T1D RESEARCH ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI PO BOX 371220 PITTSBURGH PA 15251 136171197 501(C)(3) 1389494 0 N/A N/A T1D RESEARCH KINEXUM LLC BOX 1260 - 550 RIDGE STREET HARPERS FERRY WV 25425 743079796 N/A 100000 0 N/A N/A T1D RESEARCH MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE-BLDG NE49-3182B CAMBRIDGE MA 02139 042103594 501(C)(3) 425463 0 N/A N/A T1D RESEARCH PENN STATE COLLEGE OF MEDICINE 500 UNIVERSITY DRIVE P O BOX 850 MAIL CODE H157 HERSHEY PA 17033 246000376 501(C)(3) 364548 0 N/A N/A T1D RESEARCH SEATTLE CHILDRENS HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 910564748 501(C)(3) 428940 0 N/A N/A T1D RESEARCH THE UNIVERSITY OF IOWA 5-660 BOWEN SCIENCE BUILDING IOWA CITY IA 52242 426004813 501(C)(3) 250000 0 N/A N/A T1D RESEARCH THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON PO BOX 301418 HOUSTON TX 753031418 741761309 501(C)(3) 100000 0 N/A N/A T1D RESEARCH 79 14 PART I, LINE 2: RESEARCH GRANTS ARE AWARDED BY BREAKTHROUGH T1D WITH THE SUPPORT OF BREAKTHROUGH T1D'S RESEARCH COMMITTEE COMPRISED OF BREAKTHROUGH T1D BOARD MEMBERS AND OTHER VOLUNTEERS OR THE BREAKTHROUGH T1D BOARD OF DIRECTORS FOLLOWING THE RECOMMENDATIONS OF AN IN-HOUSE TEAM OF PROFESSIONAL SCIENTIFIC STAFF AND WITH INPUT FROM EXTERNAL SCIENTIFIC REVIEWERS. THE REVIEW PROCESS INCLUDES THE FOLLOWING CRITERIA: (1) THE SCIENTIFIC MERIT OF THE PROPOSED RESEARCH OUTLINED IN A GRANT APPLICATION AND (2) THE RELATIONSHIP OF THE PROPOSED RESEARCH TO BREAKTHROUGH T1D'S GOAL TO IMPROVE LIVES TODAY AND TOMORROW BY ACCELERATING LIFE-CHANGING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D AND ITS COMPLICATIONS. THE SCIENTIFIC RESEARCH TEAM AND GRANT ADMINISTRATION STAFF MAINTAIN CLOSE CONTACT WITH GRANTEES, PROVIDING ADVICE AND EVALUATION, REVIEWING PROGRESS REPORTS, REVIEWING RESEARCH EXPENDITURES VERSUS AGREED BUDGETS, AND HELPING DISSEMINATE RESEARCH RESULTS. X 1 0 X X X X X 1 0 0 0 0 0 0 1 0 AARON KOWALSKI CHIEF EXECUTIVE OFFICER 561917 0 225000 0 75000 0 14950 0 53728 0 930595 0 0 0 STEVEN ST PETER MANAGING DIRECTOR, T1D FUND 417591 0 350000 0 0 0 19125 0 36981 0 823697 0 0 0 HELEN ELLIAS MANAGING DIR. T1D FUND (END 6/24) 344145 0 225000 0 0 0 14932 0 30465 0 614542 0 0 0 ROBERT KING CFAO/TREASURER 439354 0 80800 0 0 0 17343 0 7497 0 544994 0 0 0 PAMELA MORRISROE CHIEF MARKETING OFFICER 371368 0 74000 0 0 0 17545 0 28847 0 491760 0 0 0 KATHLEEN SEITZ CHIEF GLOBAL DEVELOPMENT OFFICER 375373 0 71300 0 0 0 14965 0 12111 0 473749 0 0 0 SANJOY DUTTA PHD CHIEF SCIENTIFIC OFFICER 351535 0 65000 0 0 0 8933 0 1623 0 427091 0 0 0 BALA BALASUBRAMANIAN CHIEF INFORMATION OFFICER 286719 0 55100 0 0 0 13259 0 45670 0 400748 0 0 0 SYDNEY YOVIC CHF. STR OFC/CHF OF STAFF (END 6/24) 266943 0 51300 0 0 0 12435 0 51045 0 381723 0 0 0 TRACY MIDO CHIEF HUMAN RESOURCES OFFICER 304089 0 56300 0 0 0 11282 0 1613 0 373284 0 0 0 AMY MONTALTO VICE PRESIDENT, VOLUNTEER ENGAGEMENT 255150 0 19800 0 0 0 11778 0 49300 0 336028 0 0 0 ESTHER LATRES VICE PRESIDENT, RESEARCH 248778 0 27500 0 0 0 10043 0 1584 0 287905 0 0 0 TIMOTHY DOYLE FORMER OFFICER 0 0 0 0 268477 0 0 0 0 0 268477 0 0 0 JESSE RABEN CHIEF LEGAL & RISK OFC, SECRETARY 158339 0 7300 0 0 0 7088 0 30828 0 203555 0 0 0 JAMES MCDONALD BOARD LIAISON 123629 0 12000 0 0 0 5577 0 3009 0 144215 0 0 0 PART I, LINE 1A HOUSING ALLOWANCE CEO AARON KOWALSKI RECEIVED A TAXABLE HOUSING ALLOWANCE AS PER THE TERMS OF HIS EMPLOYMENT AGREEMENT. THE TOTAL FOR CALENDAR YEAR 2023 WAS $75,000. PART I, LINE 4A SEVERANCE PAYMENTS TIMOTHY DOYLE RECEIVED SEVERANCE PAYMENT AS PER THE TERMS OF HIS EMPLOYMENT AGREEMENT. THE TOTAL IS AS FOLLOWS: TIMOTHY DOYLE - $268,477 SEVERANCE PAYMENTS ARE REPORTED ON SCHEDULE J, PART II, COLUMN (B)(III) AS OTHER REPORTABLE COMPENSATION. PART I, LINE 7 NON-FIXED PAYMENTS BREAKTHROUGH T1D AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEES' PERFORMANCE. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2, PART II, COLUMN (B) (II). E BEARD SEE BELOW 78605 SEE BELOW 0 SCHEDULE L, PART IV, LINE 1 (B) E. BEARD HAS A FAMILY RELATIONSHIP WITH GRANT BEARD, A MEMBER OF BREAKTHROUGH T1D'S BOARD OF DIRECTORS.(D) EMPLOYMENT BY BREAKTHROUGH T1D. X 88 108844 NET PROCEEDS OF SALE X 234 12199034 NET PROCEEDS OF SALE 0 0 1 1 SCHEDULE M, PART I, LINE 32B THIRD PARTY ASSISTANCE CHARITABLE ADULT RIDES AND SERVICES (CARS) IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO BREAKTHROUGH T1D. DONORS CALL A TOLL FREE NUMBER AND ARE PUT IN CONTACT WITH A TOWING SERVICE IN THEIR AREA. AFTER THE CAR IS DONATED, CARS HANDLES ALL IRS 1098-C REPORTING. FOR THE YEAR ENDED 6/30/2024, CARS RAISED $150,095, WITH SELLING EXPENSES OF $14,040 AND FUNDRAISING SERVICE FEES OF $27,211. BREAKTHROUGH T1D DOES NOT PAY CARS ANY EXPENSES OR FEES DIRECTLY. BREAKTHROUGH T1D RECEIVED $108,844 OF NET REVENUE FROM CARS IN FY 2024. SCHEDULE M, PART I PART I, LINE 9 REPORTS THE NUMBER OF CONTRIBUTIONS OF SECURITIES THAT WERE MADE TO BREAKTHROUGH T1D. FORM 990, PART I, LINE 1 AND PART III, LINE 1 - ORGANIZATION'S MISSION IN JUNE 2024, JDRF INTERNATIONAL INTRODUCED A NEW BRAND AND UNDERWENT A LEGAL NAME CHANGE TO BREAKTHROUGH T1D. TO INFORM THIS CHANGE, WE SURVEYED THOUSANDS OF PEOPLE WHO LIVE WITH T1D, THEIR CAREGIVERS, RESEARCHERS, HEALTHCARE PROFESSIONALS, AND INDUSTRY LEADERS, AND OUR NEW BRAND REFLECTS WHO WE ARE TODAY AND THE FUTURE BREAKTHROUGHS WE'RE PURSUING FOR THE T1D COMMUNITY. BREAKTHROUGH T1D (FORMERLY JDRF) WORKS TIRELESSLY TO ACCELERATE BREAKTHROUGHS TO CURE, PREVENT, AND TREAT TYPE 1 DIABETES (T1D) AND ITS COMPLICATIONS. WE CONTINUALLY EXPAND OUR SCIENTIFIC KNOWLEDGE, OUR CONNECTIONS AND COLLABORATIONS, OUR PARTNERS AND GLOBAL PRESENCE TO UNLOCK THE SCIENCE THAT WILL MAKE T1D A THING OF THE PAST. WHILE WE DRIVE TOWARD CURES, WE STRIVE JUST AS HARD TO DEVELOP THERAPIES TO HELP PEOPLE RIGHT NOW. BREAKTHROUGH T1D AND OUR SCIENTISTS ARE LEADING T1D RESEARCH AROUND THE WORLD. WE ADDRESS KEY GAPS TO MOVE RESEARCH FASTER AND FARTHER ACROSS THE DEVELOPMENT AND ACCESS PIPELINE AND TO TRANSLATE BREAKTHROUGHS INTO NEW THERAPIES FOR PEOPLE WITH T1D. THIS ENABLES US TO ADVANCE SCIENCE WITH THE MOST POTENTIAL AND TO DRIVE RESEARCH THAT ATTRACTS MORE RESOURCES AND SCIENTIFIC EXPERTISE TO THE FIELD. WE INVEST IN THE EARLY STAGES, ALLOWING RESEARCHERS TO PURSUE INNOVATIVE IDEAS AND APPROACHES THAT WILL LEAD TO BREAKTHROUGH TREATMENTS. BREAKTHROUGH T1D ALSO WORKS TO DRIVE NEW THERAPIES AND TECHNOLOGIES TO MARKET SO THEY GET INTO THE HANDS OF PEOPLE WITH T1D MORE QUICKLY. WE EDUCATE HEALTHCARE PROVIDERS AND PEOPLE WITH T1D ABOUT THERAPIES AND DEVICES SO THEY UNDERSTAND THEIR OPTIONS FOR MANAGING T1D. AND WE CONNECT THE T1D COMMUNITY TO CREATE A GLOBAL COMMUNITY OF SUPPORT FOR ANYONE AFFECTED BY T1D. FROM FUNDING INNOVATIVE RESEARCH TO ADVOCATING FOR GOVERNMENT ACTION AND PROVIDING A SUPPORT STRUCTURE FOR OUR COMMUNITY, NO OTHER ORGANIZATION DOES MORE TO DRIVE TOWARD CURES FOR T1D WHILE MAKING LIFE WITH THE DISEASE BETTER FOR THE PEOPLE WHO FACE IT. SINCE OUR FOUNDING, BREAKTHROUGH T1D HAS FUNDED MORE THAN $2.5 BILLION IN RESEARCH AND HAS MADE SIGNIFICANT PROGRESS IN UNDERSTANDING THE DISEASE, DRIVING TOWARD CURES FOR IT, AND IMPROVING THE LIVES OF PEOPLE WITH IT. OUR ACTIONS - THROUGH ADVOCACY AND OUR OWN INVESTMENTS IN T1D RESEARCH - INFLUENCE OTHER ORGANIZATIONS, CORPORATIONS AND GOVERNMENT AGENCIES TO FOLLOW OUR LEAD AND DIRECT ADDITIONAL FUNDING TOWARD T1D RESEARCH. TODAY, EVERY $1 BREAKTHROUGH T1D INVESTS IN RESEARCH ATTRACTS AN ADDITIONAL $2.57 TO THE FIELD. FOR FISCAL YEAR 2024, BREAKTHROUGH T1D'S APPROXIMATELY $146 MILLION IN RESEARCH FUNDING AND INVESTMENTS ATTRACTED $375 MILLION IN ADDITIONAL INVESTMENT IN T1D RESEARCH FROM U.S. AND INTERNATIONAL GOVERNMENTS, NONGOVERNMENTAL ORGANIZATIONS AND PEER CHARITABLE ORGANIZATIONS, AND INDUSTRY AND CORPORATE PARTNERS. FORM 990, PART III, LINE 4A: RESEARCH GRANTS BREAKTHROUGH T1D HAS PLAYED A SIGNIFICANT ROLE IN NEARLY EVERY T1D ADVANCEMENT--DRUG, DEVICE, CELL THERAPY--MADE IN THE LAST 50+ YEARS. OUR FUNDING SUPPORTS MORE THAN 400 ACTIVE T1D RESEARCH GRANTS IN THE UNITED STATES AND 20+ OTHER COUNTRIES AROUND THE WORLD, INCLUDING 159 GRANTS IN FY2024 ALONE, PLUS 78 CLINICAL TRIALS. WE LEVERAGE PARTNERSHIPS WITH ACADEMIA, INDUSTRY, AND CLINICIANS TO ACCELERATE THE MOST PROMISING RESEARCH OPPORTUNITIES. OUR HIGHEST PRIORITY IS DEVELOPING CURES FOR T1D AND IMPROVING LIVES OF THOSE LIVING WITH THE DISEASE TODAY, INCLUDING RESEARCH IN GLUCOSE CONTROL AND PREVENTION OF T1D COMPLICATIONS. THE FULL IMPACT OF BREAKTHROUGH T1D'S RESEARCH INVESTMENT EXTENDS WELL BEYOND DIRECT FUNDING. THROUGH ADVOCACY AND INFLUENCE, BREAKTHROUGH T1D DRIVES FUNDING FROM OTHER SOURCES INTO T1D RESEARCH AND HAS HELPED SECURE PASSAGE OF THE SPECIAL DIABETES PROGRAM, PUTTING NEARLY $3.5 BILLION IN FEDERAL FUNDING TOWARD T1D RESEARCH OVER THE LAST TWO DECADES. ADDITIONALLY IN 2016, BREAKTHROUGH T1D FOUNDED THE T1D FUND: A BREAKTHROUGH T1D VENTURE (T1DFUND.ORG), WHICH IS A WHOLLY OWNED SUBSIDIARY OF BREAKTHROUGH T1D. THE T1D FUND IS AN IMPACT INVESTING FUND FOCUSED ON ACCELERATING LIFE-CHANGING SOLUTIONS TO TREAT, PREVENT, AND ULTIMATELY CURE TYPE 1 DIABETES (T1D). FUNDED THROUGH DONATIONS FROM BREAKTHROUGH T1D, OTHER FOUNDATIONS, AND PRIVATE INDIVIDUALS, THE T1D FUND IS A UNIQUE CONSTRUCT THAT INVESTS IN FOR-PROFIT ENTITIES, MOSTLY IN THE EARLY VENTURE CAPITAL STAGE, BUT ALSO IN PUBLIC COMPANIES. IN ACCORDANCE WITH GAAP, THE T1D FUND'S TOTAL INVESTMENTS AS OF JUNE 30, 2024, TOTALING $65.6 MILLION, ARE REFLECTED IN THE BALANCE SHEET (PART X) AND NOT INCLUDED WITHIN BREAKTHROUGH T1D'S RESEARCH-RELATED MISSION EXPENSE. BREAKTHROUGH T1D'S DIVERSIFIED RESEARCH PORTFOLIO INCLUDES A FOCUS ON CURING T1D AND IMPROVING LIVES THROUGH THEIR ACADEMIC GRANT FUNDING AND INDUSTRY DISCOVERY & DEVELOPMENT PARTNERSHIP (IDDP) PRODUCT-BASED INITIATIVES FOCUSED ON ALL STAGES OF RESEARCH. CURING T1D WE FACE TWO KEY CHALLENGES IN CURING T1D. WE MUST PREVENT, STOP, OR REVERSE THE (1) LOSS OF INSULIN-PRODUCING BETA CELLS AND (2) THE IMMUNE SYSTEM'S ATTACK ON BETA CELLS. BREAKTHROUGH T1D IS ACCELERATING OUR WORK IN CURING T1D BY FOCUSING ON THREE AREAS THAT HAVE ADVANCED DRAMATICALLY OVER THE YEARS: EARLY DETECTION OF T1D, CELL THERAPIES, AND DISEASE-MODIFYING THERAPIES. EARLY DETECTION OF T1D: FOCUS ON EXPANDING AWARENESS OF AND ACCESS TO SCREENING FOR T1D-RELATED AUTOANTIBODIES, AND MONITORING FOR PEOPLE WHO TEST POSITIVE. DONOR-FUNDED RESEARCH HAS DISCOVERED THAT HAVING TWO OR MORE T1D-SPECIFIC ANTIBODIES MEANS THAT YOU HAVE AN ALMOST 100% CHANCE OF DEVELOPING DIABETES IN YOUR LIFETIME. WITH ONE BLOOD TEST, YOU CAN FIND OUT--BEFORE SYMPTOMS APPEAR--IF YOU ARE AT RISK. THIS CAN REDUCE THE RISK OF DIABETIC KETOACIDOSIS AND HOSPITALIZATION AT THE ONSET OF SYMPTOMS AND IDENTIFY PEOPLE WHO CAN TAKE PART IN CLINICAL TRIALS TO DELAY OR PREVENT T1D. CELL THERAPIES: FOCUS ON REPLACING INSULIN-PRODUCING BETA CELLS FROM OUTSIDE SOURCES SUCH AS STEM CELLS OR NON-HUMAN CELLS. THROUGH DONOR-FUNDED RESEARCH, WE NOW KNOW THAT WHEN SOMEONE HAS T1D, THEIR OWN BODY BEGINS ATTACKING AND DESTROYING THE BETA CELLS THAT CREATE INSULIN. IF WE CAN REPLACE BETA CELLS, WE CAN HELP FIND CURES FOR T1D. THERE IS EARLY BUT CRUCIAL PROGRESS SEEN IN RECENTLY REPORTED CLINICAL TRIALS WHERE BETA CELL REPLACEMENT HAS MADE ADVANCES TOWARD INSULIN THERAPY INDEPENDENCE, BETTER T1D MANAGEMENT, AND LONGEVITY OF THE THERAPIES. DISEASE-MODIFYING THERAPIES: RESEARCH HAS SHOWN THAT A PERSON'S IMMUNE SYSTEM MISTAKENLY DESTROYS THE BODY'S BETA CELLS, RENDERING THE PERSON INSULIN-THERAPY DEPENDENT FOR LIFE. IF WE CAN FIND WAYS TO KEEP THE IMMUNE SYSTEM FROM ATTACKING AND DESTROYING BETA CELLS, PROVIDE WAYS TO PROTECT AND TO SPUR THEM, AND DEVELOP TREATMENTS THAT CAN SLOW, HALT, OR REVERSE T1D, AT ANY AGE OR STAGE OF THE DISEASE, WE WILL BE ON THE PATHWAY TO PREVENTION AND CURES FOR T1D. IMPROVING LIVES T1D BRINGS WITH IT DAILY STRUGGLES AND STRESSES THAT MAKE THE CHALLENGES OF LIVING A HEALTHY AND LONG LIFE WITH T1D VERY REAL. BREAKTHROUGH T1D FIGHTS EVERY DAY TO ADVANCE RESEARCH THAT REDUCES THE BURDEN OF LIVING WITH T1D AND KEEPS PEOPLE AS HEALTHY AS POSSIBLE UNTIL WE HAVE CURES. SPECIFICALLY, WE ARE STRIVING TO IMPROVE LIVES BY ACCELERATING THE DEVELOPMENT OF DRUGS, DEVICES, BEHAVIORAL HEALTH INTERVENTIONS, AND COMBINATIONS OF THESE TO IMPROVE SHORT- AND LONG-TERM HEALTH OUTCOMES AND QUALITY OF LIFE, THROUGH THE FOLLOWING THREE PROGRAMS: GLUCOSE CONTROL: WE KNOW THAT FEWER THAN 30% OF PEOPLE WITH T1D IN THE U.S. CONSISTENTLY MAINTAIN TARGET BLOOD-GLUCOSE LEVELS--MEANING THAT 70% ARE AT RISK OF SERIOUS HEALTH ISSUES. AIMING TO ENSURE OUR COMMUNITY IS HEALTHY WHEN CURES ARE FOUND, WE WILL CONTINUE TO FOCUS ON HELPING THOSE WITH T1D MANAGE GLUCOSE LEVELS AND OVERALL METABOLIC BALANCE, INCLUDING IMPROVED ARTIFICIAL PANCREAS TECHNOLOGY, DEVELOPING NEXT-GENERATION INSULINS, AND DEVELOPING NEW DRUGS THAT CONTROL GLUCOSE AND OTHER METABOLIC FACTORS IN NOVEL WAYS. COMPLICATIONS: FOCUS ON ACCELERATING THERAPIES THAT PREVENT AND TREAT EYE, KIDNEY, AND HEART DISEASE. MORE THAN 90% OF PEOPLE WITH T1D DEVELOP SOME LEVEL OF EYE DISEASE WITHIN 20 YEARS OF DIAGNOSIS, 1 IN 4 DEVELOP KIDNEY DISEASE, AND HEART ATTACKS AND STROKES CAUSE APPROXIMATELY 3 OUT OF EVERY 4 DEATHS IN PEOPLE WITH T1D. BREAKTHROUGH T1D DIRECTS FUNDS TO DEVELOP AND IMPROVE EYE, KIDNEY, AND HEART DISEASE TREATMENTS, SO THAT PEOPLE AT RISK CAN TAKE STEPS TO INTERVENE EARLY IN THE DISEASE PROCESS. PSYCHOSOCIAL HEALTH: FOCUS ON REDUCING THE PSYCHOSOCIAL CHALLENGES OF T1D. EARLY RESEARCH HAS SHOWN THAT THE BURDEN OF LIVING WITH T1D TAKES A TOLL BEYOND THE PHYSICAL COMPLICATIONS, OFTEN AFFECTING PEOPLE'S SOCIAL, BEHAVIORAL, AND EMOTIONAL WELL-BEING, KNOWN COLLECTIVELY AS PSYCHOSOCIAL HEALTH. WE AIM TO REDUCE THE CHALLENGES THROUGH INCREASING THE NUMBER OF AND PROVIDING ACCESS TO PSYCHOLOGISTS TRAINED IN T1D, SUPPORTING RESEARCH INITIATIVES TO IMPROVE PSYCHOSOCIAL HEALTH AND OUTCOMES, AND EDUCATING THE T1D COMMUNITY ABOUT THE PSYCHOSOCIAL IMPACT OF THE DISEASE. FORM 990, PART III, LINE 4B: RESEARCH SUPPORT BREAKTHROUGH T1D'S IN-HOUSE TEAM OF SKILLED AND CREDENTIALED SCIENTIFIC, POLICY, AND GOVERNMENT RELATIONS PROFESSIONALS PLAYS A CRITICAL ROLE IN LEADING AND SUPPORTING THE RESEARCH STRATEGY AND DISTRIBUTION OF RESEARCH FUNDS FROM BREAKTHROUGH T1D--AND OUR PARTNER ORGANIZATIONS--TOWARD CREATING A WORLD WITHOUT T1D. OUR PROFESSIONALS IDENTIFY, EVALUATE, AND INFLUENCE GROUNDBREAKING RESEARCH FOR FUNDING AND WORK WITH OTHER FOUNDATIONS, GOVERNMENTS, AND INDUSTRY PARTNERS TO ACCELERATE OUR SHARED MISSION. BREAKTHROUGH T1D PROFESSIONALS WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE RESEARCH CAN PROCEED WITHOUT DELAY AND THAT ADVANCES ARE WELL UNDERSTOOD BY HEALTHCARE DECISION MAKERS. AS PART OF THESE EFFORTS, BREAKTHROUGH T1D ORGANIZES AND FUNDS SCIENTIFIC MEETINGS, SYMPOSIA, AND CONFERENCES TO ENSURE THAT BREAKTHROUGH T1D'S RESEARCH STRATEGY IS ALIGNED WITH THE NEEDS OF THE T1D COMMUNITY AND ALLOW OUR EXPERTS TO PROVIDE SCIENTIFIC UPDATES ON THE RESEARCH WE FUND. THIS EFFORT ENSURES THAT ALL THE RESEARCH IS CONTINUALLY SHARED AND BUILT UPON BY T1D RESEARCHERS AROUND THE GLOBE. THE STRATEGIC ADVISORY PANEL (SAP) IS COMPOSED OF FIVE ESTABLISHED T1D EXPERTS IN VARIOUS ASPECTS OF THE FIELD, INCLUDING PEDIATRIC ENDOCRINOLOGY, PREVENTION, AND TREATMENT OF T1D, IMMUNOTHERAPIES, REGULATORY, AND DRUG DEVELOPMENT. THE SAP CONTRIBUTES TO BREAKTHROUGH T1D SCIENTISTS' STRATEGIC PLANNING REGARDING RESEARCH FUNDING GOALS AND PRIORITIES. BREAKTHROUGH T1D BRINGS TOGETHER THE BEST MINDS IN THE FIELD, WHICH ENHANCES BREAKTHROUGH T1D'S ABILITY TO FORECAST FUTURE SCIENTIFIC DIRECTION, JUDGE THE POTENTIAL EFFECTIVENESS OF NEW PATHWAYS, AND IDENTIFY GAPS WHERE OUR FUNDING CAN MAKE THE MOST IMPACT. FORM 990, PART III, LINE 4C: PUBLIC EDUCATION BREAKTHROUGH T1D IS UNIQUELY QUALIFIED TO PROVIDE PUBLIC EDUCATION ABOUT TYPE 1 DIABETES AND ITS COMPLICATIONS. BREAKTHROUGH T1D'S EFFORTS IMPACT NOT ONLY THE MILLIONS OF PEOPLE LIVING WITH T1D, THEIR FAMILIES, AND THE GENERAL PUBLIC, BUT ALSO THOSE AT RISK FOR DEVELOPING THE DISEASE. T1D STRIKES BOTH CHILDREN AND ADULTS, AND THE CRITICAL ADJUSTMENT PERIOD FOLLOWING A DIAGNOSIS CAN BE OVERWHELMING. THAT'S WHY WE SUPPORT FAMILIES AND INDIVIDUALS NAVIGATING THIS CHALLENGING TIME. WE ALSO EDUCATE PEOPLE ABOUT THE WARNING SIGNS OF T1D, AIMED AT ENSURING TIMELY DIAGNOSES AND REDUCING THE POTENTIAL CATASTROPHIC CONSEQUENCES OF UNDIAGNOSED T1D. BREAKTHROUGH T1D ALSO PROVIDES INFORMATION AND UPDATES ABOUT CURRENT RESEARCH DIRECTIONS AND PROGRESS AND ABOUT HUMAN CLINICAL TRIALS THAT ARE SEEKING PARTICIPANTS (INCLUDING THROUGH OUR CLINICAL TRIALS CONNECTION MATCHING TOOL: WWW.BREAKTHROUGHT1D.ORG/CLINICAL-TRIALS). THROUGH ALL OF OUR NATIONAL U.S. CHAPTERS; FIVE INTERNATIONAL AFFILIATES IN AUSTRALIA, CANADA, ISRAEL, THE NETHERLANDS, AND UNITED KINGDOM; BREAKTHROUGH T1D DRIVES TOWARD CURES WHILE MEETING THE T1D COMMUNITY'S DIVERSE NEEDS, CONNECTING PEOPLE WITH LOCAL SUPPORT, EXPERT RESOURCES, AND THE GLOBAL EFFORT TO CREATE A WORLD WITHOUT T1D. FORM 990, PART VI, SECTION A, LINE 4 SIGNIFICANT CHANGES TO ITS GOVERNING DOCUMENTS THE ARTICLES OF INCORPORATION WERE AMENDED TO CHANGE THE CORPORATE NAME FROM JDRF INTERNATIONAL TO BREAKTHROUGH T1D AS OF MAY 9, 2024. A COPY OF THE CERTIFICATE OF AMENDMENT WAS FILED WITH THE PENNSYLVANIA CORPORATION BUREAU ON MAY 9, 2024. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 REVIEW PROCESS BREAKTHROUGH T1D HAS A RIGOROUS STANDARD APPROACH TO REVIEWING ITS 990. THE ORGANIZATION'S ACCOUNTING MANAGER WORKS WITH ITS OUTSIDE TAX PREPARERS TO PREPARE THE RETURN AND ALL SUPPORTING SCHEDULES. THE DRAFT RETURN IS REVIEWED BY A NUMBER OF INDIVIDUALS, INCLUDING BREAKTHROUGH T1D'S CHIEF FINANCIAL OFFICER, OTHER EXECUTIVES, ITS EXTERNAL SENIOR TAX ADVISOR AND OTHERS AS NECESSARY TO ENSURE ACCURACY. ANY QUESTIONS AND CHANGES WITH RESPECT TO THE DRAFT RETURNS ARE ADDRESSED. FOLLOWING THIS PROCESS, THE RETURN IS REVIEWED BY BREAKTHROUGH T1D'S AUDIT AND RISK COMMITTEE OF THE BOARD OF DIRECTORS WITH ITS OUTSIDE TAX ADVISORS. ONCE APPROVED, THE RETURN IS DISTRIBUTED TO ALL MEMBERS OF BREAKTHROUGH T1D'S BOARD OF DIRECTORS FOR REVIEW AND COMMENT BEFORE IT IS FILED WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY COVERED PERSONS COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM AND ACKNOWLEDGE THE BREAKTHROUGH T1D CODE OF ETHICS AT THE BEGINNING OF EACH FISCAL YEAR. COVERED PERSONS INCLUDE: MEMBERS OF THE INTERNATIONAL BOARD OF DIRECTORS, DIRECTORS EMERITUS, MEMBERS OF THE GLOBAL MISSION BOARD, CHAPTER DIRECTORS AND OFFICERS, DIRECTORS OF THE T1D FUND, AND MEMBERS OF THE T1D FUND INVESTMENT COMMITTEE. WHEN A CONFLICT IS DISCLOSED, THE COVERED PERSON SHALL ABSTAIN FROM PARTICIPATING IN DECISIONS AND/OR DISCUSSIONS INVOLVING BREAKTHROUGH T1D'S BUSINESS OR RELATIONSHIP WITH THE RELEVANT THIRD PARTY. IF THE COVERED PERSON IS ASKED TO ABSTAIN, THE COVERED PERSON MAY STILL BE PERMITTED TO STATE HIS OR HER POSITION ON SUCH MATTER AND TO ANSWER PERTINENT QUESTIONS AND INQUIRIES RELATING THERETO. THE COVERED PERSON MAY BE ASKED TO LEAVE THE MEETING DURING THE DISCUSSION OF AND/OR VOTE ON THE MATTER INVOLVING THE RELEVANT THIRD PARTY. FORM 990, PART VI, SECTION B, LINE 15 EXECUTIVE COMPENSATION POLICY BREAKTHROUGH T1D'S BOARD OF DIRECTORS CHARGES A TALENT AND COMPENSATION COMMITTEE TO DEVELOP AND RECOMMEND A COMPENSATION PHILOSOPHY THAT APPLIES TO ALL EMPLOYEES OF THE ORGANIZATION, INCLUDING RECOMMENDATIONS REGARDING THE COMPENSATION AND BENEFITS OF ORGANIZATION SENIOR MANAGEMENT FOR APPROVAL BY THE BOARD OF DIRECTORS. THE COMMITTEE WORKS IN COLLABORATION WITH THE CEO AND THE CHIEF HUMAN RESOURCES OFFICER AND OTHER SENIOR STAFF PERSONNEL IN THE BREAKTHROUGH T1D HUMAN RESOURCES DEPARTMENT TO ENSURE THAT 1) THE ORGANIZATION'S TALENT STRATEGY SUPPORTS AND IS ALIGNED WITH ITS OVERALL ORGANIZATION STRATEGIES; 2) BREAKTHROUGH T1D IS IN COMPLIANCE WITH IRS GUIDELINES FOR DETERMINING REASONABLENESS IN PAY PRACTICES; AND 3) OVERALL COMPENSATION FOR THE ORGANIZATION'S KEY EXECUTIVES IS COMPETITIVE AND ALIGNED WITH PAY PHILOSOPHY. TO ATTRACT AND RETAIN TOP SCIENTIFIC AND EXECUTIVE TALENT TO ADVANCE ITS MISSION, THE ORGANIZATION PAYS COMPETITIVE AND APPROPRIATE SALARIES AS DETERMINED BY ANALYSIS OF RELIABLE DATA AND INPUT FROM INDEPENDENT THIRD-PARTY CONSULTANTS. THE REVIEW OF ORGANIZATION EXECUTIVE COMPENSATION AND BENEFITS UNDER THE PROCEDURES NOTED ABOVE IS COMPLETED ANNUALLY BY AN INDEPENDENT COMPENSATION COMMITTEE, AND THE BASIS FOR THEIR DETERMINATION IS DOCUMENTED CONTEMPORANEOUSLY IN THE MINUTES OF THE COMMITTEE'S MEETINGS, INCLUDING MOST RECENTLY ON JUNE 30, 2024. SIMILARLY, A SEPARATE TALENT AND COMPENSATION COMMITTEE OF THE T1D FUND IS CHARGED WITH ENSURING THAT 1) THE FUND'S TALENT STRATEGY SUPPORTS AND IS ALIGNED WITH ITS OVERALL ORGANIZATION STRATEGIES; 2) BREAKTHROUGH T1D IS IN COMPLIANCE WITH IRS GUIDELINES FOR DETERMINING REASONABLENESS IN PAY PRACTICES; AND 3) OVERALL COMPENSATION FOR THE FUND'S KEY EXECUTIVES IS COMPETITIVE AND ALIGNED WITH PAY PHILOSOPHY. FORM 990, PART VI, SECTION C, LINE 19 PUBLIC DOCUMENTS THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE: WWW.BREAKTHROUGHT1D.ORG. THE PUBLIC MAY ACCESS COPIES OF BREAKTHROUGH T1D'S W-9, ANNUAL REPORTS, 990 TAX RETURNS, 501(C)(3) IRS LETTER, AND AUDITED FINANCIALS, AT THE FOLLOWING LINK: HTTPS://WWW.BREAKTHROUGHT1D.ORG/ABOUT/FINANCIALS/ T1D FUND A BREAKTHROUGH T1D VENTURE LLC C/O BREAKTHROUGH T1D - 200 VESEY ST NEW YORK NY 10281 274967989 FUNDR/INVEST DE 23683258 199022819 BREAKTHROUGH T1D SCHEDULE R, PART I, LINE (1B) THE PRIMARY ACTIVITY FOR THE T1D FUND IS FUNDRAISING AND INVESTING IN TYPE 1 DIABETES RESEARCH. PLEASE SEE DETAILED DESCRIPTION ON SCHEDULE O, PART III, LINE 4A, STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS FOR RESEARCH GRANTS.